BB&T upgraded to Outperform from Neutral at Credit Suisse Credit Suisse upgraded BB&T to Outperform citing valuation and high growth at the company's lite insurance subsidiary. The firm raised its price target for shares to $46.50 from $43.
BB&T downgraded to Neutral from Buy at Compass Point Compass Point downgraded BB&T to Neutral and lowered its price target to $39 from $41 following the disappointing Q1 report. The firm said loan growth continues to lag, and when combined with NIM pressures and expansion uncertainties into new markets, will prevent adequate book value growth vs. peers. Compass Point recommends investors stay on the sidelines until there is more clarity on the potential benefits from the Susquehanna acquisition.